Payment overview · 2025
General Payments
$17,105.46
147 reported records · 26 companies
Healthcare provider profile · identity verified
Suhail Sharif, MD
Allopathic & Osteopathic Physicians|Surgery|Surgical Oncology · FORT WORTH, TX · NPI 1083753677
Verified facts
What the public records show
CMS Open Payments records show Suhail Sharif, MD received $17,105.46 in general payments during 2025 across 147 reported records.
Ethicon Inc. accounted for 33.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 41 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Gattex.
Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GATTEX as an associated drug or biological on 5737 records involving 3682 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Gattex by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Ethicon Inc. | Unresolved — no canonical attribution shown | $5,791.54 | 33.9% | 3 | 2025 |
| Kerecis Limited | Unresolved — no canonical attribution shown | $4,973.91 | 29.1% | 28 | 2025 |
| Ethicon US, LLC | Unresolved — no canonical attribution shown | $2,076.16 | 12.1% | 65 | 2025 |
| Medical Device Business Services, Inc. | Unresolved — no canonical attribution shown | $869.17 | 5.1% | 6 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$720.93 | 4.2% | 8 | 2025 |
| Fujifilm Healthcare Americas Corporation | Unresolved — no canonical attribution shown | $496.75 | 2.9% | 3 | 2025 |
| Acera Surgical, Inc. | Unresolved — no canonical attribution shown | $441.46 | 2.6% | 3 | 2025 |
| HISTOSONICS, INC. | Unresolved — no canonical attribution shown | $335.78 | 2.0% | 1 | 2025 |
| Royal Biologics, Inc. | Unresolved — no canonical attribution shown | $328.53 | 1.9% | 3 | 2025 |
| Dilon Technologies, Inc. | Unresolved — no canonical attribution shown | $202.07 | 1.2% | 3 | 2025 |
| Integra LifeSciences Corporation | Unresolved — no canonical attribution shown | $197.13 | 1.1% | 4 | 2025 |
| Baxter Healthcare | Unresolved — no canonical attribution shown | $168.28 | 1.0% | 3 | 2025 |
| Alafair Biosciences, Inc. | Unresolved — no canonical attribution shown | $162.71 | 0.9% | 1 | 2025 |
| Smith+Nephew, Inc. | Unresolved — no canonical attribution shown | $66.63 | 0.4% | 3 | 2025 |
| Lexington Medical, Inc. | Unresolved — no canonical attribution shown | $43.70 | 0.3% | 2 | 2025 |
| Davol Inc. | Unresolved — no canonical attribution shown | $39.50 | 0.2% | 1 | 2025 |
| Molnlycke Health Care US, LLC | Unresolved — no canonical attribution shown | $28.25 | 0.2% | 1 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $26.71 | 0.2% | 1 | 2025 |
| Elucent Medical | Unresolved — no canonical attribution shown | $24.34 | 0.1% | 1 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $23.06 | 0.1% | 1 | 2025 |
| Access Pro Medical, LLC | Unresolved — no canonical attribution shown | $17.57 | 0.1% | 1 | 2025 |
| Enterra Medical, Inc. | Unresolved — no canonical attribution shown | $17.23 | 0.1% | 1 | 2025 |
| Pacira Pharmaceuticals Incorporated | Unresolved — no canonical attribution shown | $16.16 | 0.1% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $15.24 | 0.1% | 1 | 2025 |
| AngioDynamics, Inc. | Unresolved — no canonical attribution shown | $14.98 | 0.1% | 1 | 2025 |
| Sirtex Medical Inc | Unresolved — no canonical attribution shown | $7.67 | 0.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $6,580.02 | 140 |
| Consulting Fee | $6,240.00 | 2 |
| Travel and Lodging | $2,285.44 | 4 |
| Education | $2,000.00 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Echelon Flex Normalized: echelon flex |
Device | Ethicon Inc., Ethicon US, LLC | $6,558.69 | 23 | 2025 |
Source payment records
|
|||||
| VISTASEAL Normalized: vistaseal |
Biological | Ethicon Inc., Ethicon US, LLC | $6,343.41 | 25 | 2025 |
Source payment records
|
|||||
| Enseal X1 Normalized: enseal x1 |
Device | Ethicon Inc., Ethicon US, LLC | $5,928.58 | 4 | 2025 |
Source payment records
|
|||||
| DERMABOND Normalized: dermabond |
Device | Ethicon Inc. | $5,791.54 | 3 | 2025 |
Source payment records
|
|||||
| Kerecis GraftGuide Normalized: kerecis graftguide |
Device | Kerecis Limited | $4,973.91 | 28 | 2025 |
Source payment records
|
|||||
| Kerecis SurgiClose Normalized: kerecis surgiclose |
Device | Kerecis Limited | $4,973.91 | 28 | 2025 |
Source payment records
|
|||||
| SIGNIA Normalized: signia |
Device | Medtronic, Inc. | $509.32 | 4 | 2025 |
Source payment records
|
|||||
| ARIETTA PRECISION Normalized: arietta precision |
Device | Fujifilm Healthcare Americas Corporation | $496.75 | 3 | 2025 |
Source payment records
|
|||||
| Restrata Wound Matrix Normalized: restrata wound matrix |
Device | Acera Surgical, Inc. | $441.46 | 3 | 2025 |
Source payment records
|
|||||
| ECHELON ENDOPATH Normalized: echelon endopath |
Device | Ethicon US, LLC | $408.09 | 8 | 2025 |
Source payment records
|
|||||
| Harmonic Normalized: harmonic |
Device | Ethicon US, LLC | $260.91 | 5 | 2025 |
Source payment records
|
|||||
| HEMOBLAST BELLOWS Normalized: hemoblast bellows |
Device | Dilon Technologies, Inc. | $202.07 | 3 | 2025 |
Source payment records
|
|||||
| Integra Normalized: integra |
Device | Integra LifeSciences Corporation | $197.13 | 4 | 2025 |
Source payment records
|
|||||
| Integra Dermal Regeneration Template Normalized: integra dermal regeneration template |
Device | Integra LifeSciences Corporation | $197.13 | 4 | 2025 |
Source payment records
|
|||||
| OMNIGRAFT Normalized: omnigraft |
Device | Integra LifeSciences Corporation | $197.13 | 4 | 2025 |
Source payment records
|
|||||
| SURGIMEND Normalized: surgimend |
Device | Integra LifeSciences Corporation | $197.13 | 4 | 2025 |
Source payment records
|
|||||
| PERCLOT Normalized: perclot |
Device | Baxter Healthcare | $168.28 | 3 | 2025 |
Source payment records
|
|||||
| VersaWrap Normalized: versawrap |
Device | Alafair Biosciences, Inc. | $162.71 | 1 | 2025 |
Source payment records
|
|||||
| STRATAFIX Normalized: stratafix |
Device | Ethicon US, LLC | $155.10 | 5 | 2025 |
Source payment records
|
|||||
| TRANSORB Normalized: transorb |
Device | Medtronic, Inc. | $154.97 | 1 | 2025 |
Source payment records
|
|||||
| Aeon Endostapler & Echelon Flex Powered Stapler Normalized: aeon endostapler echelon flex powered stapler |
Device | Lexington Medical, Inc. | $43.70 | 2 | 2025 |
Source payment records
|
|||||
| Surgiphor Normalized: surgiphor |
Device | Davol Inc. | $39.50 | 1 | 2025 |
Source payment records
|
|||||
| LINX REFLUX MANAGEMENT SYSTEM Normalized: linx reflux management system |
Device | Ethicon US, LLC | $36.94 | 1 | 2025 |
Source payment records
|
|||||
| PICO 7 Normalized: pico 7 |
Device | Smith+Nephew, Inc. | $33.47 | 1 | 2025 |
Source payment records
|
|||||
| COLLAGENASE SANTYL Normalized: collagenase santyl |
Drug | Smith+Nephew, Inc. | $33.16 | 2 | 2025 |
Source payment records
|
|||||
| Enseal Normalized: enseal |
Device | Ethicon US, LLC | $32.95 | 2 | 2025 |
Source payment records
|
|||||
| Endopath Xcel Normalized: endopath xcel |
Device | Ethicon US, LLC | $32.85 | 2 | 2025 |
Source payment records
|
|||||
| LIGASURE Normalized: ligasure |
Device | Medtronic, Inc. | $32.48 | 1 | 2025 |
Source payment records
|
|||||
| EVARREST Normalized: evarrest |
Biological | Ethicon US, LLC | $31.11 | 1 | 2025 |
Source payment records
|
|||||
| Mepilex Border Post-Op Ag Normalized: mepilex border post op ag |
Device | Molnlycke Health Care US, LLC | $28.25 | 1 | 2025 |
Source payment records
|
|||||
| Mepitel Normalized: mepitel |
Device | Molnlycke Health Care US, LLC | $28.25 | 1 | 2025 |
Source payment records
|
|||||
| Mepitel Ag Normalized: mepitel ag |
Device | Molnlycke Health Care US, LLC | $28.25 | 1 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $26.71 | 1 | 2025 |
Source payment records
|
|||||
| EMPRINT Normalized: emprint |
Device | Medtronic, Inc. | $24.16 | 2 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $23.06 | 1 | 2025 |
Source payment records
|
|||||
| MATRIDERM Normalized: matriderm |
Device | Access Pro Medical, LLC | $17.57 | 1 | 2025 |
Source payment records
|
|||||
| Exparel Normalized: exparel |
Drug | Pacira Pharmaceuticals Incorporated | $16.16 | 1 | 2025 |
Source payment records
|
|||||
| GATTEX Normalized: gattex |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $15.24 | 1 | 2025 |
Source payment records
|
|||||
| NANOKNIFE Normalized: nanoknife |
Device | AngioDynamics, Inc. | $14.98 | 1 | 2025 |
Source payment records
|
|||||
| SIR-Spheres Microspheres Normalized: sir spheres microspheres |
Device | Sirtex Medical Inc | $7.67 | 1 | 2025 |
Source payment records
|
|||||
| DERMABOND PRINEO Normalized: dermabond prineo |
Device | Ethicon US, LLC | $1.42 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| GATTEX gattex |
2025 | Gattex | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference |
2025 | GATTEX open payments reported associated product |
CMS Open Payments — General Payments 5737 supporting records · 3682 recipient NPIs · example record 1223616328 |
Gattex · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Doxycycline Hyclate | Doxycycline Hyclate | 28 | 28 |
| Metronidazole | Metronidazole | 16 | 16 |
| Neomycin Sulfate | Neomycin Sulfate | 16 | 16 |
| Pantoprazole Sodium | Pantoprazole Sodium | 15 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 14 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 14 | 14 |
| Tramadol Hcl | Tramadol Hcl | 14 | suppressed |
| Gattex | Teduglutide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $17,105.46 · 147 records | Ethicon Inc. | ARIETTA PRECISION, Aeon Endostapler & Echelon Flex Powered Stapler, COLLAGENASE SANTYL, DERMABOND, DERMABOND PRINEO, ECHELON ENDOPATH, EMPRINT, EVARREST, Echelon Flex, Endopath Xcel, Enseal, Enseal X1, Exparel, GATTEX, HEMOBLAST BELLOWS, Harmonic, Integra, Integra Dermal Regeneration Template, JOURNAVX, Kerecis GraftGuide, Kerecis SurgiClose, LIGASURE, LINX REFLUX MANAGEMENT SYSTEM, MATRIDERM, Mepilex Border Post-Op Ag, Mepitel, Mepitel Ag, NANOKNIFE, OMNIGRAFT, PERCLOT, PICO 7, Restrata Wound Matrix, SIGNIA, SIR-Spheres Microspheres, STRATAFIX, SURGIMEND, Surgiphor, TRANSORB, VISTASEAL, VersaWrap, ZENPEP | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Gattex play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Takeda Pharmaceuticals U.S.A., Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error